A new prognosis for lung cancer

Major advances in diagnostics and therapeutics

Historically, lung cancer is a disease with limited treatment options, late-diagnosis, and a limited spectrum of chemotherapies that have toxic side effects and a poor response rate, but there have been several exciting developments in recent years.

In the latest instalment of ERS Vision, Professor Stephen Holgate explores recent advances in lung cancer diagnostics, changes in clinical trial design and improved standards of care, and discusses the optimistic future of lung cancer treatment.

supported by a grant from astrazeneca